Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2017 pubmed 48 citations

Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.

Peng. Yun Y; Zhang. Suhan S; Zhao. Yi Y; Liu. Yi Y; Yan. Bing B

Key Findings

  • Anti‑MDA5‑positive dermatomyositis patients show higher circulating LL‑37 and cell‑free DNA, markers of NET formation.
  • Higher LL‑37 levels correlate with a lung disease marker (KL‑6), suggesting a link to interstitial lung disease severity.
  • Serum from anti‑MDA5‑positive patients can trigger normal neutrophils to produce more NETs in lab experiments.

Practical Outcomes

  • For most biohackers, this study offers limited direct action. It highlights LL‑37 as a potential biomarker for lung complications in a rare autoimmune condition, but does not suggest any supplement, dosage, or lifestyle change that could be applied to improve longevity or performance.

Summary

Researchers found that people with a certain skin‑muscle disease (dermatomyositis) who have a specific auto‑antibody (anti‑MDA5) also have higher levels of a protein called LL‑37 in their blood. This protein is part of neutrophil extracellular traps (NETs), which seem to be linked to lung damage in these patients.

Abstract

In dermatomyositis (DM), anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody (autoAb) marks a subtype with low grade or absent muscle inflammation but frequent and rapidly progressive interstitial lung disease (ILD). The pathogenesis of ILD remains poorly unknown. The aim of the study is to explore whether neutrophil extracellular traps (NETs) are involved in the development of ILD in DM patients with anti-MDA5 autoAb. Patients with clinically amyopathic dermatomyositis (CADM, n&#xa0;=&#xa0;20), classic dermatomyositis (cDM, n&#xa0;=&#xa0;30), polymyositis (PM, n&#xa0;=&#xa0;20), and healthy controls (HC, n&#xa0;=&#xa0;20) were enrolled. Anti-MDA5 autoantibody and Krebs von den Lungen-6 (KL-6) were detected by ELISA. Circulating levels of NETs were assessed by the quantification of both serum cell-free DNA (cfDNA) and LL-37 (cathelicidin LL-37). Immunofluorescent staining was used to visualize NETs ex vivo. The elevated circulating NETs level was detected in DM patients with ILD complication. Compared to anti-MDA5 Ab<sup>-</sup> DM patients, anti-MDA5 Ab<sup>+</sup> DM patients had the higher concentrations of serum cfDNA (293&#xa0;&#xb1;&#xa0;69 vs 252&#xa0;&#xb1;&#xa0;63&#xa0;ng/ml; P&#xa0;=&#xa0;0.035) and serum LL-37 (0.6&#xa0;&#xb1;&#xa0;1.0 vs 0.2&#xa0;&#xb1;&#xa0;0.2&#xa0;ng/ml; P&#xa0;=&#xa0;0.026). Positive correlations were established between serum levels of cfDNA and KL-6 in DM patients (r <sub>s</sub>&#xa0;=&#xa0;0.4422, P&#xa0;=&#xa0;0.0003). anti-MDA5 Ab<sup>+</sup> sera, other than anti-MDA5 Ab<sup>-</sup> sera, could induce greater numbers of normal neutrophils to form NETs in vitro. These data suggest that aberrant NETs formation may be involved in the pathogenesis of ILD in DM patients with anti-MDA5 autoAb.

Study Information

Provider

pubmed

Year

2017

Date

2017-08-25T00:00:00.000Z

DOI

10.1007/s10067-017-3799-y

Citations

48

References

39